Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


DME competitive bidding momentum

This article was originally published in The Gray Sheet

Executive Summary

One-year freeze on durable medical equipment spending, followed by competitive bidding implementation, likely will be included in the final Medicare reform package, according to device stakeholders. The new technology provisions also are coming under scrutiny, as conferees look to keep the "Medicare Prescription Drug & Modernization Act" of 2003 (HR 1, S 1) under the $400 bil. figure proposed by President Bush. Working with lawmakers, AdvaMed has succeeded in reducing the new tech score to $1.5 bil., but conferees may try to lower the amount to $1 bil. or less...

You may also be interested in...

Medicare Reform Prospects Beginning To Fade – CMS Administrator Scully

CMS Administrator Tom Scully is no longer confident that the Medicare reform conference committee will be able to agree on a final product, let alone produce a bill that can pass both chambers

Finance Watch: Silverback, Kinnate, Sigilon Launch December’s First IPOs

Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.

BioCryst’s Oral Option To Take On Injectables In HAE Prophylaxis Market

Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts